In Cambodia, multidrug-resistant Plasmodium falciparum undermines the treatment of uncomplicated malaria, and new therapeutic options are needed.
Resistance to piperaquine has been associated with the amplification of the plasmepsin II gene in Cambodia.
LAMP is a simple, rapid and accurate molecular tool for detecting gestational and placental malaria, being able to overcome the limited sensitivity of LM and RDT.
The interpretation of RDT results requires some training but is a good alternative to the FST.
Plasmodium vivax parasites have a unique dormant stage that can cause relapses weeks or months after the initial infection.
Two mass drug administrations (MDA) against falciparum malaria were conducted in 2015–16, one as operational research in northern Cambodia, and the other as a clinical trial in western Cambodia.
Clusters of malaria carriers were malaria species specific and often located remotely, outside village centres.
Widespread use of spatial repellents would not fill all protective gaps, but, if their entomological efficacy can be ascertained, outdoor application has the potential to enhance vector control strategies in Cambodia.
The findings of high P. vivax IC50 to mefloquine and piperaquine, but not chloroquine, suggest significant drug pressure from drugs used to treat multidrug resistant P. falciparum in Cambodia.